桡动脉与隐静脉作为冠状动脉旁路移植术第二移植物的荟萃分析
该荟萃分析纳入14项研究共20,931例患者,比较桡动脉与隐静脉作为第二移植物在冠状动脉旁路移植术中的早期和晚期临床结局。结果显示两组围术期死亡率、心肌梗死和卒中无差异,但桡动脉组长期死亡率显著低于隐静脉组(24.5% vs 34.2%,IRR 0.74,95%CI 0.63-0.87,P<.001)。
要点
- 桡动脉作为第二移植物与隐静脉相比,6.6年随访死亡率相对风险降低26%。
- 围术期死亡率、心肌梗死和卒中在两组间无显著差异。
- 长期心肌梗死和再次血运重建率在两组间无显著差异。
核心结论
- 与隐静脉相比,使用桡动脉作为第二移植物在6.6年随访时与死亡率相对风险降低26%相关。
研究设计与样本
- 检索MEDLINE和EMBASE数据库,纳入比较桡动脉与隐静脉用于孤立性冠状动脉旁路移植术的研究。
- 共纳入14项研究,20,931例患者,平均随访6.6年。
- 采用随机效应荟萃分析,提取长期死亡、再次血运重建和心肌梗死的时间-事件结局为发生率比(IRR)及95%置信区间(95%CI),围术期死亡、卒中和心肌梗死提取比值比(OR)。
- 敏感性分析包括留一法分析和荟萃回归。
主要发现
- 围术期死亡率桡动脉组1.25%,隐静脉组1.33%(OR 0.93,95%CI 0.68-1.28)。
- 围术期心肌梗死(OR 0.96,95%CI 0.59-1.56)和卒中(OR 0.70,95%CI 0.43-1.13)两组无差异。
- 长期死亡率桡动脉组24.5%,隐静脉组34.2%(IRR 0.74,95%CI 0.63-0.87,P<.001)。
- 随访期间心肌梗死(IRR 0.76,95%CI 0.42-1.36)和再次血运重建(IRR 0.68,95%CI 0.42-1.09)两组无差异。
- 荟萃回归显示桡动脉生存优势独立于年龄、性别、糖尿病和心室功能。
临床怎么用
- 在冠状动脉旁路移植术中选择第二移植物时,桡动脉可作为隐静脉的合理替代以改善长期生存。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Individual studies may be limited by sample size to detect differences in late survival between radial artery (RA) or saphenous vein graft (SVG) as a second conduit for coronary artery bypass surgery. Here we undertook a meta-analysis of the best evidence available on the comparison of early and late clinical outcomes of the RA and the SVG. METHODS: MEDLINE and EMBASE were searched for studies comparing use of the RA versus SVG for isolated coronary artery bypass surgery. Time-to-event outcomes for long-term mortality, repeat revascularization, and myocardial infarction (MI) were extracted as incidence rate ratios (IRR) with 95%confidence intervals (95% CI). Odds ratios (OR) were extracted for perioperative mortality, stroke, and MI. A random effects meta-analysis was performed. Sensitivity analyses included leave-one-out-analyses and meta-regression. RESULTS: Among 1201 articles, 14 studies (20,931 patients) were included (mean follow-up: 6.6 years). Operative mortality was 1.25% in the RA versus 1.33% in the SVG group (OR, 0.93; 95% CI, 0.68-1.28). No difference in perioperative MI (OR, 0.96; 95% CI, 0.59-1.56) or stroke (OR, 0.70; 95% CI, 0.43-1.13) was found between RA and SVG. Long-term mortality (mean follow-up 6.6 years) was 24.5% in RA versus 34.2% in SVG group (IRR, 0.74; 95% CI, 0.63-0.87, P < .001). No difference in follow-up MI or repeat revascularization was found (IRR, 0.76; 95% CI, 0.42-1.36 and IRR, 0.68; 95% CI, 0.42-1.09 respectively). At meta-regression, RA survival advantage was independent of age, sex, diabetes, and ventricular function. CONCLUSIONS: Compared with the SVG, using the RA as the second conduit is associated with a 26% relative risk reduction in mortality at 6.6-year follow-up.
引用
- Gaudino M, Rahouma M, Abouarab A, et al. Radial artery versus saphenous vein as the second conduit for coronary artery bypass surgery: A meta-analysis. J Thorac Cardiovasc Surg. 2018. PMID: 30551962. doi:10.1016/j.jtcvs.2018.08.123
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。